During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

There was no difference in risk for lenalidomide plus cyclophosphamide, lenalidomide plus dexamethasone, and melphalan alone. "These data suggest that the future role of oral melphalan in ...

Lenalidomide offers an exciting advance in the treatment of the 5q– MDS patient. It has the ability to alter the course of MDS by inducing hematologic and cytogenetic responses, resulting in ...

Contacts IR Contacts United States Ran Meir (267) 468-4475 Israel Yael Ashman 972 (3) 914-8262 PR Contacts United States Kelley Dougherty (973) 658-0237 Yonatan Beker (973) 264 7378 ...

Lenalidomide, an immunomodulatory agent with antiangiogenic and antineoplastic properties, is a standard treatment for initial and relapsed multiple myeloma.

1 Belada D, M.D., Ph.D., et al. A Phase 1b, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in ...